Researcher
Nick Devoogdt
- Keywords:Medicine, Applied biological sciences, biotechnology
- Disciplines:Medical biotechnology diagnostics, Industrial molecular engineering of nucleic acids and proteins, Molecular diagnostics, Applied immunology, Nuclear imaging, Cancer diagnosis, Cancer therapy, Biomarker evaluation, Non-clinical studies, Radiopharmacy, Medical molecular engineering of nucleic acids and proteins
Affiliations
- Medical Imaging (Research group)
Member
From31 Dec 2010 → Today - Supporting clinical sciences (Department)
Member
From1 Oct 2021 → Today - Supporting clinical sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2021 - Supporting clinical sciences (Department)
Member
From1 Jan 2014 → Today - Supporting clinical sciences (Department)
Member
From1 Mar 2013 → 31 Dec 2017 - Medical Imaging and Physical Sciences (Department)
Member
From1 Mar 2013 → 31 Dec 2013 - Medical Imaging and Physical Sciences (Department)
Member
From1 Oct 2007 → 30 Sep 2009 - Cellular and Molecular Immunology (Research group)
Member
From30 Sep 1999 → 29 Sep 2007 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 1997 → 28 Feb 2013
Projects
1 - 10 of 29
- SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancerFrom1 Nov 2022 → TodayFunding: BOF - projects
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → TodayFunding: IOF - technology validation in real environment
- IOF POC Project SYNALI : Development and application of a Synthetic Nanobody LibraryFrom1 Jan 2022 → TodayFunding: IOF - technology concept exploration
- Nanobody-based AXL targeting and combination treatment for acute myeloid leukemia and multiple myelomaFrom1 Jan 2022 → TodayFunding: FWO research project
- Evaluation of an in vivo pre-targeting approach for targeted radionuclide therapy of cancer using clickable anti-B7-H3 single domain antibodies.From1 Nov 2021 → TodayFunding: FWO fellowships
- Development of a novel chemoenzymatic technology to generate radiofluorinated PET tracersFrom1 Nov 2021 → TodayFunding: FWO junior postdoctoral fellowship
- IOF PoC “MOTIF: MOdification of T cells In situ for altered Functionality”From1 Jan 2021 → 31 Dec 2022Funding: IOF - technology concept exploration
- CONVICT: sentencing Cancer cells to death through ONcolytic Virotherapy and modulation of the Immune Checkpoint TIGITFrom1 Nov 2020 → TodayFunding: FWO fellowships
- GEAR: Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Jan 2020 → TodayFunding: IOF - technology validation in real environment, IOF - mandates
- Evaluation of an anti-idiotype NanoCAR-T cell approach for the treatment of Multiple MyelomaFrom1 Jan 2020 → TodayFunding: FWO research project
Publications
1 - 10 of 131
- Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody(2023)
Authors: Maxime Nachit, Christopher Montemagno, Romain Clerc, Mitra Ahmadi, François Briand, Sandrine Bacot, Nick Devoogdt, Cindy Serdjebi, Catherine Ghezzi, Thierry Sulpice, et al.
- Nanobodies for the Early Detection of Ovarian Cancer(2022)
Authors: Lan-Huong Tran, Geert-Jan Graulus, Cécile Vincke, Natalia Smiejkowska, Anne Kindt, Nick Devoogdt, Serge Muyldermans, , Wanda Guedens
- Radiotheranostic Agents in Hematological Malignancies(2022)
Authors: Jo Caers, Elodie Duray, Louise Vrancken, Guillaume Marcion, Valentina Bocuzzi, Kim De Veirman, Ahmet Krasniqi, Margaux Lejeune, Nadia Withofs, Nick Devoogdt, et al.
- Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model(2022)
Authors: Thomas Ertveldt, L De Beck, Kirsten De Ridder, Hanne Locy, Wout de Mey, Cleo Goyvaerts, Quentin Lecocq, Hannelore Ceuppens, Yannick De Vlaeminck, Robin Maximilian Awad, et al.
Pages: 1136-1148 - Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy(2022)
Authors: Cristina Barca, Christoph M Griessinger, Andreas Faust, Dominic Depke, Markus Essler, Albert D Windhorst, Nick Devoogdt, Kevin M Brindle, Michael Schäfers, Bastian Zinnhardt, et al.
- The antigen-binding moiety in the driver's seat of CARs(2022)
Authors: Heleen Hanssens, Fien Meeus, Kim De Veirman, Karine Breckpot, Nick Devoogdt
Pages: 306-342 - The road to personalized myeloma medicine(2022)
Authors: Janik Puttemans, Benoit Stijlemans, Marleen Keyaerts, Sam Vander Meeren, Wim Renmans, Karel Fostier, Pieterjan Debie, Heleen Hanssens, Magdalena Rodak, Marek Pruszynski, et al.
Pages: 159-169 - Emerging applications of nanobodies in cancer therapy(2022)
Authors: Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W M De Groof, et al.
Pages: 143-199 - Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha(2021)
Authors: Karen De Vlaminck, Ema Romão, Janik Puttemans, Ana Rita Pombo Antunes, Daliya Kancheva, Isabelle Scheyltjens, Jo Agnes Van Ginderachter, Serge Muyldermans, Nick Devoogdt, Kiavash Movahedi, et al.
- An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models(2021)
Authors: Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijalkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke, et al.
Patents
1 - 10 of 10
- Cd20 binding agents and uses thereof (Inventor)
- Radiolabelled antibody fragments for use in treating cancer (Inventor)
- A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells (Inventor)
- Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- Radiolabelled antibody fragments for use in treating cancer (Inventor)
- Human pd-l1-binding immunoglobulins (Inventor)
- A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells (Inventor)
- Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- Anti-vcam-1 nanobodies (Inventor)
- Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases (Inventor)